Upregulating CD20 expression using agents like 5-azacytidine, which has shown effectiveness in CD20-negative B-cell acute lymphoblastic leukemia, presents another strategy [14]. Here, MS4A1 is linked to B-cell acute lymphoblastic leukemia.